Is Pfizer Stock a Buy Now After Earnings?
Top Wall Street Analysts Are Bullish on These Dividend Stocks
What Eli Lilly, Novo Nordisk Earnings Reveal About the Future of GLP-1 Sales
Pfizer (NYSE:PFE Shareholders Incur Further Losses as Stock Declines 6.2% This Week, Taking Three-year Losses to 33%
Healthcare Stocks Are Turning Around. Here Are the Latest Winners. -- Barrons.com
74 S&P 500 Stocks That Can Beat the Cash Yield - BofA
As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032
Pfizer Inc. (PFE): Should You Add This GLP-1 and Weight Loss Stock to Your Portfolio Now?
Pyxis Oncology Draws Buy at Stifel on Lead Asset
Express News | Daiwa Capital Upgrades Pfizer to Outperform, Raises Price Target to $34
Pfizer Analyst Ratings
10 Health Care Stocks Whale Activity In Today's Session
Check Out What Whales Are Doing With PFE
Viatris Hits Seven-month High After Q2 Beat
Pfizer Hits 4-week Low
Should Pfizer's Strong Quarter Calm Investor Concerns About the Stock?
Big Pharma Cuts R&D, Sending Shudders Through Industry -- Heard on the Street -- WSJ
Guolian Securities: Increased attention to tumor immunology, recommend focusing on targeted drugs such as PD1/IL2 in pharmaceutical companies.
With the increasing attention to tumor immunity, and the successive launch of advantageous products, bullish on PD1/IL2 and PD1/IL15 targeted drugs.
Bicycle Therapeutics Cut at B. Riley Ahead of Data Readouts
Pfizer Tagrisso Patent Case Against AstraZeneca Upheld by Judge